Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$13.76 -2.4%	$11.17	$7.75 ▼ $19.93	$105.10M	0.49	25,741 shs	18,038 shs
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
OMER Omeros	$3.14 -0.9%	$6.19	$2.97 ▼ $13.60	$183.98M	2.42	671,349 shs	1.08 million shs
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-2.41%	+1.25%	+27.17%	+6.09%	-8.69%
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	-0.95%	+0.96%	-56.81%	-63.15%	-5.28%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	3.5242 of 5 stars	3.3	3.0	4.7	1.5	0.8	0.0
ENDP Endo International	0.2344 of 5 stars	0.0	0.0	3.5	0.0	1.7	0.0
OMER Omeros	3.6631 of 5 stars	3.4	0.0	4.4	3.1	1.7	0.6
PRTK Paratek Pharmaceuticals	0.0214 of 5 stars	0.0	0.0	1.3	0.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	139.83% Upside
ENDP Endo International	0.00	N/A	N/A	N/A
OMER Omeros	2.80	Moderate Buy	$22.50	616.56% Upside
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest OMER, PRTK, ASMB, and ENDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/11/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
4/1/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/1/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
3/25/2025	ASMB Assembly Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
3/24/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/21/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$32.15M	3.27	N/A	N/A	$7.50 per share	1.83
ENDP Endo International	$2.99B	0.00	N/A	0.06	($13.60) per share	0.00
OMER Omeros	N/A	N/A	N/A	N/A	($0.40) per share	N/A
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$61.23M	-$6.23	N/A	N/A	N/A	-144.05%	-121.46%	-34.56%	8/14/2025 (Estimated)
ENDP Endo International	-$613.24M	-$11.07	N/A	0.00	N/A	-93.31%	-34.25%	6.72%	N/A
OMER Omeros	-$117.81M	-$2.65	N/A	N/A	N/A	N/A	N/A	-49.92%	8/6/2025 (Estimated)
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A

Latest OMER, PRTK, ASMB, and ENDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
3/31/2025	Q4 2024	OMER Omeros	-$0.71	-$0.63	+$0.08	-$0.54	$0.40 million	N/A
3/20/2025	Q4 2024	ASMB Assembly Biosciences	-$1.75	-$1.57	+$0.18	-$1.57	$7.05 million	$7.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
ENDP Endo International	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	2.36	2.36
ENDP Endo International	N/A	1.86	1.62
OMER Omeros	N/A	2.96	2.96
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
ENDP Endo International	80.39%
OMER Omeros	48.79%
PRTK Paratek Pharmaceuticals	53.60%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
ENDP Endo International	1.20%
OMER Omeros	12.30%
PRTK Paratek Pharmaceuticals	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.64 million	6.03 million	Optionable
ENDP Endo International	3,103	235.14 million	232.32 million	No Data
OMER Omeros	210	58.59 million	50.82 million	Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable

OMER, PRTK, ASMB, and ENDP Headlines

Recent News About These Companies

Optinose CEO and other top executives exit after company's acquisition by Paratek

May 23, 2025 | bizjournals.com

Paratek expands commercial portfolio with Optinose

May 22, 2025 | msn.com

OptiNose Shareholders Approve Merger with Paratek

May 18, 2025 | investing.com

Paratek Pharmaceuticals to Present Clinical Data on NUZYRA® (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference

May 16, 2025 | globenewswire.com

How a Bucks County firm's multiyear pursuit of a partner led to a potential $330M deal

April 11, 2025 | bizjournals.com

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

April 10, 2025 | globenewswire.com

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M

March 21, 2025 | fiercepharma.com

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

March 21, 2025 | markets.businessinsider.com

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

March 20, 2025 | endpts.com

Optinose Shares Surge Premarket on Takeover Deal With Paratek

March 20, 2025 | marketwatch.com

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

November 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral ...

November 9, 2024 | eagletribune.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

November 8, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

October 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

July 31, 2024 | globenewswire.com

Paratek looks to bolster pneumonia antibiotic Nuzyra with win in post-marketing study

July 19, 2024 | fiercepharma.com

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

July 18, 2024 | globenewswire.com

Pharmaceuticals / Health Products Summary

April 4, 2024 | opensecrets.org

Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs

March 5, 2024 | markets.businessinsider.com

Mira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and Dates

February 24, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Viking Holdings Posts Strong Q1, Eyes Growth Ahead
By Chris Markoch | May 20, 2025
View Viking Holdings Posts Strong Q1, Eyes Growth Ahead
AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?
By Leo Miller | May 1, 2025
View AT&T, Verizon & T-Mobile: Who Won the Big 3 Telecom Battle in Q1?
Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost
By Leo Miller | May 7, 2025
View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost

OMER, PRTK, ASMB, and ENDP Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$13.76 -0.34 (-2.41%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$13.87 +0.11 (+0.80%)

As of 05/28/2025 04:04 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Omeros NASDAQ:OMER

$3.14 -0.03 (-0.95%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$3.23 +0.09 (+2.87%)

As of 05/28/2025 06:58 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time